JPRN-UMIN000018839已完成未知
Effects of Ipragliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin Therapy - Effects of Ipragliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin Therapy(SUMS-ADDIT-1)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
BW change was significantly larger in the ipragliflozin group than in the control group (-2.78 vs -0.22 kg, P < 0.0001). Total fat mass was reduced evenly in the arms, lower limbs and trunk in the ipragliflozin group. Total muscle mass and bone mineral content were maintained, but muscle mass in the arms might have been affected by ipragliflozin treatment.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Has history of receiving a SGLT-2 inhibitor 2) Contraindication to the use of ipragliflozin (history of hypersensitivity to ipragliflozin, or pregnant, etc.) 3) With severe ketosis, diabetic coma, or precoma 4) Has history of hospitalization for infection, trauma, or surgery within 6 months 5) With history or under treatment of brain infarction or transient ischemic attack 6) With an episode of angina pectoris or myocardial infarction within 6 months 7) Receiving loop diuretics 8) With orthostatic hypotension 9) Considered as inadequate by the investigator
研究者
相似试验
已完成
不适用
Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2Type 2 diabetesJPRN-UMIN000020239Shiga University of Medical Science52
已完成
4 期
SUMS-ADDIT-2Type 2 Diabetes MellitusJPRN-jRCTs051180018Morino Katsutaro52
已完成
不适用
Effects of ipragliflozin on body composition and beta-cell function in Japanese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021623St. Marianna University School of Medicine20
已完成
4 期
Phase IV study of switching from sitagliptin to ipragliflozin in obese patients with type 2 diabetesDiabetes mellitusJPRN-jRCTs031190022Ishihara Hisamitsu51
已完成
4 期
Effect of dapagliflozin, the sodium-glucose-cotransporter-2 (SGLT2) inhibitor, on fibroblast growth factor 21 (FGF21), a novel hepatokine and myokine, in Japanese patients of type 2 diabetesType 2 diabetesJPRN-UMIN000021479ational Hospital Organization Kyoto Medical Center60